Loading
A phase 2 trial of HLX26 and Serplulimab in non-small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients is a phase 2 interventional study registered as NCT05787613 by Shanghai Henlius Biotech, with 132 participants enrolled, started 2023-07-10 and due to reach its primary completion in 2026-02. Interventions recorded: HLX26, Serplulimab, Chemotherapy drug and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Henlius Biotech, Serplulimab, T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors and the tag pipeline.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer and the tag pipeline.
Shares T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares T-cell exhaustion and CAR-T persistence, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares T-cell exhaustion and CAR-T persistence, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares T-cell exhaustion and CAR-T persistence, Non-small-cell lung cancer and the tag pipeline.
Shares T-cell exhaustion and CAR-T persistence, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/